The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Anti‐infliximab IgE and non‐IgE antibodies and induction of infusion‐related severe anaphylactic reactions
Abstract
To cite this article: Vultaggio A, Matucci A, Nencini F, Pratesi S, Parronchi P, Rossi O, Romagnani S, Maggi E. Anti‐infliximab IgE and non‐IgE antibodies and induction of infusion‐related severe anaphylactic reactions. Allergy 2010; 65: 657–661. Background: Infliximab is a chimeric monoclonal antibody against TNF‐α useful in the treatment of many chronic inflammatory diseases. Severe anaphylaxis has been reported during therapy, although the exact mechanism has not been fully defined. The reactions have been related to the infliximab immunogenicity and development of specific antibodies. Aims of the study: Evaluation of the development of IgE and non‐IgE antibodies to infliximab and their relationship with infusion reaction. Methods: Seventy‐one patients (11 reactives, 11 therapeutically nonresponders, and 49 unreactive therapeutically responders) and 20 non–infliximab‐exposed control subjects (ten rheumatoid arthritis, five spondyloarthropathies, five vasculitis) were evaluated for the presence of IgE (ImmunoCAP assay), IgM, and non–isotype‐specific (ELISA assays) anti‐infliximab antibodies. Sera were obtained at baseline and during the course of treatment, before each infliximab infusion. Results: Eleven out of 71 patients had a hypersensitivity reaction to infliximab. Non–isotype‐specific anti‐infliximab antibodies were detected in eight reactive and two nonresponder patients. Three patients with severe reactions displayed anti‐infliximab IgE antibodies and positive skin testing. Detectable levels of anti‐infliximab IgM antibodies were shown in three additional IgE‐ and skin testing‐negative patients. IgE and IgM antibodies to infliximab were not detectable in the two nonresponder patients. Antibodies developed before the 2nd and the 3rd infusion, and their appearance was strictly related to the timing of the reaction. Conclusions: This report indicates that in some patients with infliximab‐related severe reactions, IgE or IgM antibodies against infliximab were detectable. The majority of reactions could be predicted by the appearance of anti‐infliximab antibodies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose
Chung, C. H., Mirakhur, B., Chan, E., Le, Q.-T., Berlin, J., Morse, M., Murphy, B. A., Satinover, S. M., Hosen, J., Mauro, D., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa074943 · Cited by 1,521
Cited by
Brockow, K., Garvey, L. H., Aberer, W., Atanaskovic‐Markovic, M., Barbaud, A., Bilo, M. B., Bircher, A., Blanca, M., Bonadonna, B., Campi, P., et al. (2013) · Allergy · doi:10.1111/all.12142 · Cited by 813
Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis
van Schouwenburg, P. A., Rispens, T., & Wolbink, G. J. (2013) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2013.4 · Cited by 438
Immunogenicity to Biotherapeutics – The Role of Anti-drug Immune Complexes
Krishna, M., & Nadler, S. G. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00021 · Cited by 389
Diagnosis and management of anaphylaxis in precision medicine
Castells, M. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.06.012 · Cited by 242
Immunogenicity of therapeutic proteins: the use of animal models
Brinks, V., Jiskoot, W., & Schellekens, H. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0523-5 · Cited by 164
Metadata
- Authors
- Vultaggio, A., Matucci, A., Nencini, F., Pratesi, S., Parronchi, P., Rossi, O., Romagnani, S., & Maggi, E.
- Venue
- Allergy
- Publisher
- Wiley
- Published
- 2010-04
- Volume
- 65
- Issue
- 5
- Pages
- 657-661
- ISSN
- 0105-4538 (ISSN-L)
- 1398-9995
- OpenAlex
- W2129592053
- Cited by
- 238
- References
- 1
- FWCI
- 8.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Anti‐infliximab IgE and non‐IgE antibodies and induction of infusion‐related severe anaphylactic reactions. https://app.cochat.ai/papers/10.1111/j.1398-9995.2009.02280.x
- The paper
- Vultaggio, A., Matucci, A., Nencini, F., Pratesi, S., Parronchi, P., Rossi, O., Romagnani, S., & Maggi, E. (2010). Anti‐infliximab IgE and non‐IgE antibodies and induction of infusion‐related severe anaphylactic reactions. Allergy. https://doi.org/10.1111/j.1398-9995.2009.02280.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.